CLINICAL_TRIALS
ClinicalTrials.gov record update
A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With a History of HeFH Who Are Not Adequately Controlled by Their Lipid Modifying Therapies
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT05425745
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:27:42.630443+00:00
- Published At
- 2025-06-11T00:00:00+00:00
- Record Updated At
- 2025-06-11
- Results Posted At
- 2025-06-11
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Dyslipidemias", "High Cholesterol", "Hypercholesterolemia", "Familial Hypercholesterolemia", "Lipid Metabolism Disorder", "Metabolic Disease", "Lipid Metabolism, Inborn Errors", "Genetic Disease, Inborn", "Hyperlipoproteinemias"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-06-11"- protocolSection.identificationModule.nctId
"NCT05425745"- protocolSection.identificationModule.officialTitle
"A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With a History of HeFH Who Are Not Adequately Controlled by Their Lipid Modifying Therapies"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE3"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2025-06-11"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.